MIAMI--(BUSINESS WIRE)--Jul 7, 2026--
DemeRx, Inc., a clinical-stage biopharmaceutical company dedicated to transforming addiction therapeutics, today announced the appointment of Michael Snitkovsky as chief operations officer, adding a seasoned biopharmaceutical executive with more than 20 years of experience advancing therapies from preclinical research through clinical development. Mr. Snitkovsky is recognized for his strategic leadership, operational rigor, and ability to unite cross‑functional and global teams around shared scientific and business objectives—capabilities that support effective risk management, development acceleration, and long‑term value creation.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260707949387/en/
“Michael brings extensive operational experience across the biopharmaceutical development spectrum and a proven track record of advancing complex programs,” said Deborah Mash, Ph.D., chief executive officer and founder of DemeRx. “His expertise in development strategy, CMC, regulatory affairs, and quality will strengthen our ability to execute as we advance our pipeline at an extraordinary regulatory moment and a pivotal time for our company. As DemeRx enters its next phase of growth, Michael’s leadership will help accelerate development activities and enhance operational readiness for upcoming clinical milestones for our lead program, DMX-1001 for the treatment of alcohol use disorder.”
“I am excited to join DemeRx at this important stage in the company’s growth,” said Mr. Snitkovsky. “I look forward to working with the team to advance our programs through clinical development. DemeRx has built a strong foundation, and I am eager to help strengthen the capabilities, partnerships, and execution needed to deliver meaningful value for patients and stakeholders.”
Mr. Snitkovsky’s experience spans operational and program leadership, Chemistry, Manufacturing, and Controls (CMC) strategy, regulatory execution, and global alliance management across neurological and psychiatric disorders, including major depressive disorder, as well as oncology, immunology, gastrointestinal, and rare diseases. His appointment supports DemeRx’s continued focus on advancing its clinical programs while building the operational infrastructure required for future development. He has led multinational collaborations, including strategic partnerships, and has overseen numerous Investigational New Drug, Clinical Trial Application, Biologics License Application, and New Drug Application submissions across major regulatory jurisdictions.
At Alnylam Pharmaceuticals, he was hired to establish a Project Management Office and lead the team responsible for commercializing the first RNA interference (RNAi) therapeutic. The approval of this drug marked a landmark achievement in biotechnology, transforming the Nobel Prize-winning discovery of RNAi into a viable, disease‑modifying class of medicines and the first commercial product for Alnylam. At Finch Therapeutics, the pioneer of the first gut‑microbiome-based therapeutics, Mr. Snitkovsky led two programs within a $70M partnership with Takeda. At Red Oak Medicines and Valerio Therapeutics, where he served as global head of operations and program and alliance leadership, he built and led cross‑functional teams across major biopharmaceutical organizations. His experience also includes consulting roles at Biogen and Sanofi, driving execution across CMC, regulatory, clinical development, and global alliances.
About DemeRx, Inc.
DemeRx, Inc. is a pioneering clinical-stage biopharmaceutical company dedicated to transforming addiction therapeutics and improving outcomes for individuals facing substance use disorders. Leveraging advanced scientific research and strategic clinical initiatives, DemeRx focuses on DMX-1001 (oral noribogaine) as a groundbreaking solution for alcohol use disorder. For more information about DemeRx, please visit http://www.demerx.com.
Michael Snitkovsky, COO of DemeRx, Inc.
DALLAS--(BUSINESS WIRE)--Jul 7, 2026--
RGP (Nasdaq: RGP), a global professional services firm, today announced the appointment of Amadally Hosseinbukus as Managing Director of its Data, Analytics & AI Practice. His appointment builds on RGP’s growing momentum helping clients move from AI ambition to governed, measurable execution — strengthening the firm’s ability to deliver enterprise-scale data, analytics, automation, and AI solutions that work inside the complexity of the business.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260707717296/en/
Organizations are currently sitting on fragmented data with inconsistent governance, unable to bridge the gap between AI ambition and AI readiness. And the pressure to drive meaningful returns is intensifying. What’s missing is the experience to architect, govern, and deliver AI at the complexity level most organizations require.
“Amadally has led large-scale AI and data programs from inside some of the world’s most successful organizations,” said Scott Rottmann, President of Consulting Services at RGP. “His experience, especially within the heavily-regulated industry of financial services, gives our clients something they don’t get from most advisors: someone who has actually delivered AI value at enterprise scale.”
Hosseinbukus brings more than 30 years of experience across AI, technology, consulting, and financial services. In his new role, Hosseinbukus will lead RGP’s AI strategy, data and analytics modernization, intelligent automation, and governance capabilities — helping clients accelerate adoption while managing risk.
“Amadally will help our clients move from AI experimentation to AI competitive advantage,” said Stephen Hook, Digital Solutions Leader at RGP.
Most recently, Hosseinbukus served as Managing Director and Global Head of Innovation and AI Delivery for Wells Fargo’s Corporate and Investment Bank, leading the firm's enterprise AI delivery strategy across Markets, Lending, and Investment Banking. He oversaw a portfolio of more than 50 strategic AI initiatives that spearheaded digital transformation, improved operating efficiency, and delivered significant, measurable business value across the organization. He built and led a 70-person cross-functional team, established the AI roadmap and execution model for the division, and drove adoption across the organization.
Prior to Wells Fargo, he spent eight years at IBM Technology & Consulting in senior roles including Lead Account Partner for a global banking client and Practice Lead Partner for IBM’s Capital Markets AI and Automation practice. Earlier, he held senior technology leadership positions at Deutsche Bank — including Global Head of Regulatory Controls Technology and Global Head of Investment Banking Sales and Client Technology — and at Credit Suisse, where he served as Chief Technology Officer for the firm’s Data & Analytics business. He holds a B.Sc. in Computer Science from the University of Durham, UK.
“AI is reshaping every industry, but sustainable value will come only from embedding it into the fabric of the business with trust, accountability, and measurable impact at its core,” said Hosseinbukus. “This is a defining moment for organizations. Those that pair bold ambition with disciplined execution and responsible governance will set the pace for innovation and long-term growth.”
About RGP
RGP (Nasdaq: RGP) has been redefining professional services for 30 years by closing the gap between advice and execution. The firm combines on-demand talent, consulting rigor, and managed services accountability to help organizations accelerate transformation while reducing risk. RGP partners with CFOs and C-suite leaders across finance, digital transformation, data, cloud, and AI — connecting strategy with execution at global scale.
Based in Dallas, Texas, with offices worldwide, RGP annually serves more than 1,500 clients through 40 physical practice offices and multiple virtual offices. As of January 2026, RGP has served 90 percent of the Fortune 100 and has been recognized by U.S. News & World Report and Forbes among the best employers and management consulting firms.
To learn more, visit www.rgp.com.
Dare to Work Differently® — for a world where execution matters.
Amadally Hosseinbukus, Managing Director, Data, Analytics & AI Practice at RGP
